EUVIMEDEUVIMED entdecken
Crossref

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Ahmad Masri, Martin S Maron, Ankit Bhatia, Maria Luisa Peña-Peña, Mark V Sherrid, Estevao Lanna Figueiredo iD, Michael Arad, Roberto Barriales-Villa, Lubna Choudhury, Brian L Claggett, Caroline J Coats, Edileide de Barros Correia und 36 weitere

New England Journal of Medicine · 28.08.2026

DOI: 10.1056/nejmoa2603021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, online erschienen am 28.08.2026. Verfasst von Ahmad Masri und 47 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health and Science University, Portland. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Cytokinetics.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (HCM) is a common condition that is associated with substantial morbidity and no proven medical therapy. Whether treatment with aficamten, a cardiac myosin inhibitor, can benefit patients with this condition is unknown. METHODS: In this phase 3, multinational, double-blind trial, we randomly assigned adults with symptomatic nonobstructive HCM in a 1:1 ratio to receive aficamten (starting dose, 5 mg; maximum dose, 20 mg) or placebo for up to 72 weeks. The dual primary end points were the change from baseline to week 36 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; range, 0 to 100, with higher scores indicating better health status). RESULTS: A total of 258 patients were assigned to receive aficamten and 259 to receive placebo. The mean age of the patients was 55.1 years, and 53.6% were women. At 36 weeks, the change in the KCCQ-CSS was 11.4 points (95% confidence interval [CI], 9.6 to 13.2) in the aficamten group and 8.4 points (95% CI, 6.6 to 10.2) in the placebo group (least-squares mean difference, 3.0 points; 95% CI, 0.5 to 5.5; P = 0.02). The mean change in the peak oxygen uptake at week 36 was 0.64 ml per kilogram of body weight per minute (95% CI, 0.32 to 0.95) in the aficamten group and -0.03 ml per kilogram per minute (95% CI, -0.35 to 0.28) in the placebo group (least-squares mean difference, 0.67 ml per kilogram per minute; 95% CI, 0.22 to 1.11; P = 0.003). Reversible reductions in left ventricular ejection fraction to less than 50% occurred in 27 patients (10.5%) receiving aficamten and in 2 patients (0.8%) receiving placebo. Serious adverse events occurred in 52 patients (20.2%) and 38 patients (14.7%), respectively. CONCLUSIONS: Among patients with symptomatic nonobstructive HCM, treatment with aficamten resulted in a significantly greater change in exercise capacity and patient-reported health status than placebo at 36 weeks. (Funded by Cytokinetics; ACACIA-HCM ClinicalTrials.gov number, NCT06081894.).

Autor:innen und Institutionen

  • Oregon Health and Science University, Portland.
  • Lahey Hospital and Medical Center, Burlington, MA.
  • Lindner Research Center, The Christ Hospital, Cincinnati.
  • General Hospital of H.U. Virgen Del Rocio, Seville, Spain.
  • Leon H. Charney Division of Cardiology, NYU Langone Health, New York.
  • NUPEC Cardio, Belo Horizonte, Brazil.

ORCID-Profile: Estevao Lanna Figueiredo, Mathew S Maurer, Jesus E Pino Moreno, Scott D Solomon, Carolyn Y Ho

Förderung

  • Cytokinetics

Zitieren

APA

Masri, A., Maron, M. S., Bhatia, A., Peña-Peña, M. L., Sherrid, M. V., Figueiredo, E. L., Arad, M., Barriales-Villa, R., Choudhury, L., Claggett, B. L., Coats, C. J., Correia, E. B., Costabel, J. P., Elliott, P. M., Silva Enciso, J. E., Garcia-Pavia, P., Ge, J., Hegde, S. M., Lewis, G. D., …, & ACACIA-HCM Investigators (2026). Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2603021

Vancouver

Masri A, Maron MS, Bhatia A, Peña-Peña ML, Sherrid MV, Figueiredo EL, et al. Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2603021

BibTeX
@article{Masri2026,
  author = {Masri, Ahmad and Maron, Martin S and Bhatia, Ankit and Peña-Peña, Maria Luisa and Sherrid, Mark V and Figueiredo, Estevao Lanna and Arad, Michael and Barriales-Villa, Roberto and Choudhury, Lubna and Claggett, Brian L and Coats, Caroline J and Correia, Edileide de Barros and Costabel, Juan Pablo and Elliott, Perry M and Silva Enciso, Jorge E and Garcia-Pavia, Pablo and Ge, Junbo and Hegde, Sheila M and Lewis, Gregory D and Lopes, Renato D and Martinez, Matthew W and Maurer, Mathew S and Miao, Zi Michael and Michels, Michelle and Mitter, Sumeet S and Pino Moreno, Jesus E and Olivotto, Iacopo and Owens, Anjali T and Poulsen, Steen H and Rader, Florian and Rowin, Ethan J and Schulze, P Christian and Sepp, Robert and Sikand, Nikhil and Solomon, Scott D and Spertus, John A and Teale, Charles and Zhao, Xiaoyan and Divanji, Punag H and Heitner, Stephen B and Jacoby, Daniel L and Kupfer, Stuart and Malik, Fady I and Salazar-Mendiguchía, Joel and Wohltman, Amy and Zhuo, Shu and Ho, Carolyn Y and ACACIA-HCM Investigators, ACACIA-HCM Investigators},
  title = {Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2603021}
}
Kostenlos starten →